中国神经再生研究(英文版) ›› 2024, Vol. 19 ›› Issue (9): 2075-2080.doi: 10.4103/1673-5374.391192

• 原著:神经损伤修复保护与再生 • 上一篇    下一篇

磁共振引导经颅超声聚焦治疗特发性震颤:一项前瞻性、单中心、单臂研究

  

  • 出版日期:2024-09-15 发布日期:2024-01-26
  • 基金资助:
    该研究由 Insightec Co. Ltd.(以色列)和中国国家老年医学临床研究中心资助

Magnetic resonance-guided focused ultrasound for essential tremor: a prospective, single center, single-arm study

Rui Zong1, #, Xuemei Li2, #, Chunyu Yin2, #, Jianfeng He3, #, Dekang Zhang3, Xiangbing Bian3, Lichao Huang1, Jiayou Zhou1, Zhipei Ling1, Lin Ma3, Xin Lou3, *, Longsheng Pan1, *, Xinguang Yu1, *   

  1. 1Seniro Department of Neurosurgery, The First Medical Center of the PLA General Hospital, Beijing, China; 2Clinics of Cadre, Department of Outpatient, The First Medical Center of the PLA General Hospital, Beijing, China; 3Department of Radiology, The First Medical Center of the PLA General Hospital, Beijing, China
  • Online:2024-09-15 Published:2024-01-26
  • Contact: Longsheng Pan, MD, PhD, panls301@163.com; Xinguang Yu, MD, xinguang_yu@263.net; Xin Lou, MD, PhD, xinlou@301hospital.com.cn.
  • Supported by:
    The study was sponsored by Insightec Co. Ltd. (Israel) and China National Clinical Research Center for Geriatrics, No. NCRCG-PLAGH-2019005 (to LP). The sponsor had no role in data acquisition, analysis, or interpretation of this paper.

摘要:

磁共振引导经颅超声聚焦治疗(MRgFUS)是一种新开发的治疗技术。国际上许多国家已经批准使用经颅磁共振治疗ET。MRgFUS靶向Vim治疗帕金森病震颤同样获得较好的效果。2018年8月,解放军总医院安装了中国第一台MRgFUS系统。设备安装后,该中心随即启动了中国地区首批关于ET治疗的临床试验研究。这项临床试验的目的是验证MRgFUS在中国人群中治疗药物难治性ET的安全性和有效性。此项前瞻性、单中心、单臂研究是全球前瞻性多中心临床试验(ClinicalTrials.gov Identifier: NCT03253991)的一部分,在解放军总医院试验中心完成,共包括10例ET患者。1年随访结果显示,临床震颤评分量表(CRST)总分基线的估计边际平均值为58.3±3.6,治疗后12个月改善到23.1±6.4。共记录了50例不良事件,主要为轻度不良事件,且通常在术后几日内即消失。研究结果提示,磁共振引导经颅超声聚焦治疗药物中国人群难治性特发性震颤也同样取得较为满意的临床效果,且安全性好。 

https://orcid.org/0000-0002-1033-1802 (Longsheng Pan); https://orcid.org/0000-0001-9399-7951 (Xinguang Yu); https://orcid.org/0000-0003-2980-5171 (Xin Lou)

Abstract: The safety and effectiveness of magnetic resonance-guided focused ultrasound thalamotomy has been broadly established and validated for the treatment of essential tremor. In 2018, the first magnetic resonance-guided focused ultrasound system in Chinese mainland was installed at the First Medical Center of the PLA General Hospital. This prospective, single center, open-label, single-arm study was part of a worldwide prospective multicenter clinical trial (ClinicalTrials.gov Identifier: NCT03253991) conducted to confirm the safety and efficacy of magnetic resonance-guided focused ultrasound for treating essential tremor in the local population. From 2019 to 2020, 10 patients with medication refractory essential tremor were recruited into this open-label, single arm study. The treatment efficacy was determined using the Clinical Rating Scale for Tremor. Safety was evaluated according to the incidence and severity of adverse events. All of the subjects underwent a unilateral thalamotomy targeting the ventral intermediate nucleus. At the baseline assessment, the estimated marginal mean of the Clinical Rating Scale for Tremor total score was 58.3 ± 3.6, and this improved after treatment to 23.1 ± 6.4 at a 12-month follow-up assessment. A total of 50 adverse events were recorded, and 2 were defined as serious. The most common intraoperative adverse events were nausea and headache. The most frequent postoperative adverse events were paresthesia and equilibrium disorder. Most of the adverse events were mild and usually disappeared within a few days. Our findings suggest that magnetic resonance-guided focused ultrasound for the treatment of essential tremor is effective, with a good safety profile, for patients in Chinese mainland. 

Key words: efficacy, essential tremor, magnetic resonance-guided focused ultrasound (MRgFUS), movement disorder, safety, stereotactic therapy, thalamotomy, ventral intermediate nucleus